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Childhood obesity is a major worldwide health problem. Intervention programs to ameliorate the rate of obesity have been
designed and implemented; yet the epidemic has no end near in sight. AMP-activated protein kinase (AMPK) has become one
of the most important key elements in energy control, appetite regulation, myogenesis, adipocyte diﬀerentiation, and cellular
stress management. Obesity is a multifactorial disease, which has a very strong genetic component, especially epigenetic factors.
The intrauterine milieu has a determinant impact on adult life, since the measures taken for survival are kept throughout life
thanks to epigenetic modiﬁcation. Nutrigenomics studies the inﬂuence of certain food molecules on the metabolome proﬁle,
raising the question of an individualized obesity therapy according to metabolic (and probably) genetic features. Metformin, an
insulin sensitizing agent, its known to lower insulin resistance and enhance metabolic proﬁle, with an additional weight reduction
capacity, via activation of AMPK. Exercise is coadjutant for lifestyle modiﬁcations, which also activates AMPK in several ways
contributing to glucose and fat oxidation. The following review examines AMPK’s role in obesity, applying its use as a tool for
childhood and adolescent obesity.
1.Introduction
Obesity is considered a new pathology in the history of
Humankind, being the new food security tendency the
one to blame for such a rising wave [1]. In the last
century, technological advances and cutting edge science
have modiﬁed human lifestyle, changing diet regimes and
physicalactivityandthereforecreatinganimbalancebetween
caloric ingestion and an energy expenditure that is not able
to compensate the caloric excess ingested. This spill-over
energy is accumulated in the adipose tissue manifesting itself
asobesitywhichisconsideredastepclosertothenewevolved
man: Homo obesus [1, 2].
The World Health Organization (WHO) has labeled
obesity as the new epidemic of the 21st century. According
to WHO projections for 2005, around 1,600 billion adults
worldwide were overweight and at least 400 million were
obese; by 2015, more than 2,3 billion adults will be over-
weight and 700 million will be obese [3] .T h ev a l u e si n
the pediatrics population are even less encouraging, with
at least 20 million overweight children of less than 5 years
of age [3]. In the United States, the prevalence has risen
in the last 30 years, with a 3,8-fold for the 6–11years. old
group (from 4% to 15,3%), and 2,6-fold for the adolescent
group (from 6% to 15,5%) [4]. Sekhobo et al. [5] published
their results based on an analysis in overweight/obesity
tendency in the low-income prescholars who were part
of the New York State Special Supplemental Nutrition
Program for Women, Infants, and Children, 2002–2007. The
prevalence of obesity raised in 2003 [3, 6], later declining
from 2003 to 2005, ﬁnally stabilizing itself at 14,7% by 2007.
Nevertheless, there was an increasing prevalence of over-
weightness during the whole study. There is no doubt that
overweight and obesity have become a major health problem
[5].
Deﬁning obesity in the pediatric group is a real challenge
due to growth (weight and height) variations in childhood
and adolescence. The International Obesity Task Force2 Journal of Obesity
(IOTF) has established that obesity and overweight will be
deﬁned by corresponding percentiles of Body Mass Index
(BMI) 25–30 at 18 years of age, and that the percentiles
will be conserved throughout the age groups. Some authors
use only BMI values to diﬀerentiate between overweight and
obesity in adolescents; nevertheless Cole et al. [7] published
the percentile tables according to age and sex. With these
tools, the Center for Disease Control (CDC) has deﬁned
overweight inetary group 2–18 years of age as BMI equal or
above 95th percentile according to age and sex. The term risk
of overweight is applied to circumscribe children with BMI
between 85th and 95th according to age and sex, since CDC
prefers not to use the term obesity for psychological/social
reasons [8, 9].
The Metabolic Syndrome has evolved from its ﬁrst
deﬁnitionbackin1998bytheWHO[10].Theﬁrstpublished
consensus was meant to detect those high-risk patients, dia-
betic or not, with any degree of glucose intolerance, hyper-
tension, dyslipidemia, and/or microalbuminuria. In 1999 the
European Group for the Study of Insulin Resistance (EGIR)
issued another set of variables for the diagnosisexcluding
microalbuminuria [11]. By 2001, the Adult Treatment Panel
III (ATPIII) announced their criteria suggesting that insulin
resistance was not necessary for the diagnosis [12]. The
International Diabetes Federation (IDF) participated in this
worldwide debate when in 2005 they published their own
deﬁnition, giving particular interest to the inﬂuence of
ethnicity in the proper diagnosis of the disease and the cut-
oﬀs being set for the patients, particularly since abdomi-
nal obesity was now proposed as a fundamental element
for its identiﬁcation [13]. In 2005, the American Heart
Association together with the National Institutes of Health,
Heart, Lung, Blood Institute (AHA/NIHHLBI) revised the
ATPIII deﬁnition, modifying normal fasting glucose levels
lowered to 100mg/dl, in accordance with the American
Diabetes Association’s new cut-oﬀ [14]. Finally, the IDF
with AHA/NIHHLBI issued the newest MS deﬁnition in
2009 [15], emphasizing need for proper individualization of
anthropometric reference values in every ethnic population.
See Table 1.
Overweight/Obesity is the most studied variable of MS
in children, and there is no oﬃcial statement on the cut-
oﬀ points for its deﬁnition in this population; in fact there
is no consensus on the existence of MS in childhood due
to its limited capacity for predicting outcomes like Type
2 Diabetes Mellitus (T2DM) and Cardiovascular disease
(CVD). Goodman et al. [16]d e m o n s t r a t e di na3 - y e a r
follow-up study that 61,1% of the children with MS lost at
least one of the variables during the trial, while 25,5% of the
children without MS acquired at least one risk factor, deﬁned
by the authors as “the instability in the diagnosis of metabolic
syndrome.” Nonetheless, one of the outcomes that have been
explored is the risk of adult obesity in the already obese
child. Around 30% of adulthood obesity starts in infancy,
with even worst consequences than compared to obese
adults who were lean. Overweight adolescents have 50%–
70% chance to become overweight/obese adults, while only
30% of the lean children will become obese in adulthood
[6, 17]. This only ensures the importance of a proper and
Table 1: Metabolic Syndrome criteria according to International
Diabetes Federation/American Heart Association/National Insti-
tutes of Health, Heart, Lung, Blood Institute, 2009.
IDF/AHA/NHLBI 200914
Three of the following:
(i) Abdominal Obesity:
Elevated waist circumference according to a population and coun-
try-speciﬁc deﬁnition.
(ii) Lipid Proﬁle:
Triglycerides ≥150mg/dL or treatment for elevated triglycerides.
(iii) Lipid Proﬁle:
HDL-c <40mg/dL in men or <50mg/dL in women.
Or treatment for reduced HDL-c.
(iv) Blood Pressure:
≥130mmHg on Systolic Pressure.
Or ≥85 mmHg on Diastolic Pressure.
Or on anti-hypertensive drug treatment in a patient with a history
of HTA.
(v) Glycemia:
Fasting glucose ≥100mg/dL.
Or on drug treatment for elevated glucose.
early intervention to minimize or completely prevent future
metabolic complications.
In 1973, two research groups described at the same
time the qualities of a protein kinase that was involved
in lipid metabolism, which was able to inhibit Acetil∼
CoACarboxilase (ACC) and 3-Hydroxi-3-MethylGlutaryl∼
CoA (HMG-CoA) Reductase [18, 19]. Later on, this kinase
was labeled AMPK (AMP activated protein kinase) since
it has been activated by increased AMP concentrations.
The enzyme has been the topic of several studies, which
have revealed its eﬀect on energy balance, mitochondrial
biogenesis,regulationoflipid/carbohydratemetabolism,and
modulation of genetic expression [20, 21].
The role of AMPK as an energy thermostat puts it at
crossroads for energy homeostasis, making it fundamen-
tal to analyze the signaling pathways involved in energy
metabolism, not only for academic purposes but also for
therapeutical goals in childhood obesity. The purpose of this
review is to analyze the role of AMPK as aninterventiontar-
getin childhood obesity.
2. Nutrition of the Fetus: Under versusOver
2.1. Food Intake Control. The regulation of food intake is a
very complicated network involving peripheral signals and
central processing, which renders behavioral patterns that
lead to weight gain or weight loss [22]. The processing of
all input signals is done between the “satiety centre” in the
ventro-medial nuclei and the “hunger centre” in the lateral
hypothalamic area, arcuate, and paraventricular nuclei. The
adiposity signals come from the pancreas and the adipose
tissue, represented by insulin and leptin; both of them are
destined to stop eating behaviour and food intake onceJournal of Obesity 3
energy stores have been ﬁlled. These signals activate the Pro-
Opio-Melanocortin/Cocaine and Amphetamine-Regulated
Transcript neurons (POMC/CART) inducing satiety (see
Figure 1).
On the other hand, gut signals usually modulate hunger
and feeding behavioral patterns [23].Glucagon-like peptide
1 (GLP-1) is an incretin which is released while eating,
inducing insulin release from the β-cellsand haltering food
consumption. Peptide YY—a member of the NPY peptide
family—is a 34-aminoacid peptide secreted by the intestine
which hinders food intake and modiﬁes gut motility (ileal
brake), and its release depends on the amount of carbohy-
drate or lipids in the ingested meal. This molecule inhibits
NPY neurons and activates POMC population, lowering ∼
30% of food intake using the Y2Receptor. PYY is negatively
correlated with the degree of adiposity with reduced values
when compared with normal weight subjects [24]. Ghrelin
is a peptide synthetized in the stomach, and it is associ-
ated with hunger. It exerts its eﬀects through the Growth
hormone secretagogue receptor in the hypothalamus and
brain stem, with the activation of Neuropeptide Y/Agouti
related Peptide (NPY/AgRP) neurons, which induces ppetite
while inhibiting POMC/CART secreting cells. Obestatin is
a 23-aminoacid byproduct of the ghrelin gene breakdown,
also synthetized in the A-cells in the stomach [25] whose
physiological role is still under consideration; yet certain
studies have linked this molecule with antiapoptotic prop-
erties in β-cell, and with inhibition of food consumption
via upregulation of GLP1 mRNA [26]. Other factors include
pancreatic peptide (PP) and oxyntomodulin (Oxm)both of
which are food intake inhibitors.
Ghrelin has been one of the most researched gut-
derived molecules in childhood obesity. Disturbances of its
pathway have been proposed as basic pathophysiology for
several diseases like: growth hormone deﬁciencies, anorexia
nervosa, cachexia, chronic heart failure, gastrointestinal
motility disorders, osteoporosis, obesity, and Prader-Willi
syndrome [27]. Ghrelin enhances AMPK activity in the
hypothalamus, lowering malonyl∼CoA levels, inducing car-
nitine palmitoyl transferase-1, elevating long chain fatty
acids, releasing NPY, and activating hunger [28]. As basic
rule of thumb, ghrelin levels are inversely correlated to
BMI, and there is a negative association between insulin
and this hormone. James et al. [29] reported that ghrelin
levels are associated with slow weight gain from birth to
3 months of age, which relates it to postnatal catch up
growth. In a study using 208 preterm children, Darendeliler
et al. [30] reported that at prepubertal ages those preterm
newborns—either small (SGA) or adequate for gestational
age (AGA)—had higher ghrelin levels compared to those at-
term newborn children. This sustained elevation of ghrelin
might be needed for the compensatory growth which they
are subjected, but it does not correlate to the degree of
catch-up growth achieved nor with the levels of insulin
found. Similar results were published the following year by
Darendeliler et al. [31] analyzing prepubertal children who
were born large for gestational age, reporting that nonobese
prepubertal youngsters had lower ghrelin levels compared
to AGA born counterparts, proposing that birth weight is
in fact a fundamental determinant in ghrelin levels during
childhood.
Maﬀeis et al. [32] proposed that meal-induction of
insulin secretion promotes a fall in ghrelin levels, and that
in insulin resistance states this blunting is reduced. Now,
even though this is true, this inhibiting eﬀect of feeding is
lost in childhood suggesting that ghrelin acts as an anabolic
hormone meant to provide the necessary substrates for
growth [33]. This feeding reducing eﬀect on ghrelin depends
on insulin availability, and its deﬁciency can explain the
observed hyperphagia in Type 1 Diabetes Mellitus [34].
Bacha and Arslanian [35] conducted a trial using overweight
children as subjects to evaluate insulin’s power of inhibition,
reporting that fasting ghrelin is determined by insulin
sensitivity regardless of adiposity.
Obesity is a multifactorial disease which has no clear
genetic cause. It is known that obesity is a heritable
syndrome, with a heritability of 0.7 to 0.8 [36]; yet the genes
at play are still pending conﬁrmation. Lessons have been
taken from monogenic syndromes like the Congenital Leptin
Deﬁciency [37–39] which is characterized by hyperphagia
and early-onset obesity. The mutations causing this disease
render a functional protein that cannot mediate appetite
control, and the patients develop hyperphagia very early
on. Subjects with this mutation are candidates for leptin
replacement since it is the defective molecule. Gibson et al.
[40] reported the 4-year treatment of a subject (with the
Δ133G mutation) with subcutaneous recombinant leptin,
providing beneﬁcial and long lasting controlling eﬀects on
hyperinsulinemia,hyperlipidemia,fatmassdistribution,and
TSH levels. Not all mutations are located on one gene nor do
they have such a profound eﬀect like the former Mendelian
syndrome; most of the genes associated with obesity [41]
interact with each other to express a phenotype that will end
with abdominal obesity. Genomewide scans have revealed
several gene candidates [41], including adiponectin (3q27)
[42, 43], adrenergic receptor α-2A (10q24-q26) [44, 45],
leptin (7q31.3) [46, 47], glucocorticoid receptor (5q31) [48],
PPARγ (3p25) [49], serotonin receptor (Xq24) [50], and
melanocortin 4 receptor (18q21) [51]. The interaction of
thesegeneswithenvironmentalfactorsaﬀectanycheckpoint
in the appetite network, either in the behavioral aspects or in
the metabolic adaptations, as can be seen in Figure 2.
The Thrifty Phenotype theory proposed by Barker [52]
tried to explain the relationship between intrauterine growth
retardation and premature death due to cardiovascular
diseaseorT2DMcomplications(seeFigure 3).Hepostulated
that according to the insult enforced on the fetus, the
reprogramming of several axes would determine the fetus’
survival during the pregnancy phase; yet the necessary
measures imprinted for salvationare deleterious during adult
life. Fetal malnutrition can be achieved by several ways,
but the overall outcome is always the same: hypoglycemia
and hypoxia. Small placentas, which have not acquired
enough spiral arteries remodeling, have trouble oxygenating
and nurturing the conceptus, developing a hypoxic placental
milieu [53]. It has been proposed that modiﬁcations in
the adipoinsular axis of the fetus promote hyperinsulinism
and hyperleptinemia and confer the necessary epigenetic4 Journal of Obesity
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Figure 1: The Food Intake network is a complex system compromising several levels. See text for further information. CCK: cholecystoki-
nine; GLP-1, Glucagon-like peptide 1, NTS, nucleus of the solitary tract, PVN, paraventricular nucleus; PYY, Peptide YY.
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Figure 2: Appetite control is a very complex network, which has to
intertwine genetic factors, nutritional signals, and environmental
determinants. The making of metabolic switches and acquiring
food-seeking related behavioral patterns is the ﬁnal combination to
manage food intake.
work-up to maintain this during postnatal life [54]. Fetuses
small for their age are usually dysmorphic, with small bodies
compared to the proportion of their head (brain sparing)
[55], low fat mass concentrations, and blunted response to
hyperglycemia apparently from small β-cell ontogeny and
mass [56].
Leptin can be detected as early as 17-week gestation [57],
modulating adipose tissue development. Leptin acts as a
lipostat in fetal life, giving information about fat maturity
and proportions. In animal models—as in humans—fetal fat
has brown and white adipose tissue characteristics, and it
goes along with the very fundamental fact of being born with
a matured hypothalamic-pituitary axis [58]. It is noteworthy
to remark that adipose tissue grows in locules (uni and
multiple), and there is always a dominant unilocular tissue
whichcorrelateswithleptinconcentrations.Theseunilocular
spots have peculiar (transitional) adipocytes with abundant
mitochondria, uncoupling protein 1 (UCP1), and Prolactin
receptor-long type that are brown tissue characteristics; yet
they are capable of secreting leptin (white adipose tissue
trait). Lipid synthesis is a very expensive process, using
39MJ/kg (compared with carbohydrates which consumes
15–25MJ/kg), and in the fetus this pathway depends on
oxygen and metabolic substrates supply [58]. In light of
this, if the mother modiﬁes the amount of food and the
quality of it, the proper maturation of fetal adipose tissue
can be modulated. Indeed, several animal models have
shown that maternal chronic hypoxia, hypoglycemia, and
hypoinsulinemia are related to low levels of mRNA for leptin
[59, 60].
Vickers et al. [61] published their ﬁndings on the fetal
origins of hyperphagia and obesity using Virgin Wistar rats
that were mated randomly and subsequently were divided
into 2 groups: those with food restriction and those with
food ad libitum. The pups born from the malnourished
group were smaller at birth and had higher food intake
in the immediate postnatal period, and this behaviour was
enhanced with a hypercaloric diet. They concluded that
hyperinsulinism and hyperleptinemia are responsible for
fetal programming and adult hyperphagia, obesity, and
high blood pressure. During that same year, Ekert et al.
[62] reported that maternal nutrition during pregnancy
in fact reprograms leptin secretion and this pattern is
maintained even in adulthood. The research group used the
pig model, whose mothers were fed a restricted diet during
the whole pregnancy (whole pregnancy undernourishment),
and half of these were then fed 35% more food during the
second quarter of the pregnancy (a migestation malnutrition
and late pregnancy recuperation). Leptin’s expression was
measured by determining mRNA of the protein in the
subcutaneous adipose tissue of the mothers, reporting a
negative correlation between birth weight and leptin levelsJournal of Obesity 5
Pregnancy∼maternal catabolic phase = redistribution of nutrients for fetal growth
Placental∼size and transfer capacity = f e t a lg r o w t hc u r v e ∼fetal weight and viability
Utero placent al transfer deﬁcit∼hypoglycemia + hypoxia = IUGR
Metabolic-induced imprinting∼fetal origins of the diseases of the adult
Figure 3: The intrauterine life is very delicate balance between fetal growth and placental transport capacity which depends on the mother’s
vascular capacity. If the placenta is not fully developed (anomalous insertion, second wave invasion incomplete, or other maternal morbidity
like long-term diabetes, hypertension or other related disease with vasculopathy), decreased blood ﬂow through the umbilical cord will
generate several survival responses in the fetus, all with the aim of reaching a viable weight and enough lung maturation to survive outside
the womb. The mechanisms are energy-savers and try to protect the brain from damage. This metabolically induced imprinting lasts very
wellintoadulthood,beingthekeyfeatureinthedevelopmentofchronicdiseaseslikeObesity,Type2diabetes,Stroke,Cardiovasculardisease,
among others.
Low grade inﬂammation
AMPK
MEF2
AAC
Adipogenesis Lipogenesis
Intramyocellular
lipid deposits
Myogenesis
FOXO
β-catenin
Maternal obesity/T2DM
Figure 4: If the baby develops in a proinﬂammatory milieu, it is another study. The Barker hypothesis comes with an inﬂammatory
componentbutitisbasicallyaimedatthemotherduetoplacentalhypoxia(itisbasicallyresponsibleforthehypertensionandprothrombotic
features of Preeclampsia). In the Macrosomic fetus low-grade inﬂammation takes it is toll on AMPK activation, which due to it is
inhibition 2 basic pathways are modiﬁed. First, Acetyl∼CoA loss of inhibition, which lets loose adipogenesis and lipogenesis with increased
intramyocellular lipid deposits. Second, while preadipocyte is diﬀerentiated to mature adipocytes, myogenesis is being stalled due to loss of
activation of expression of genes that regulate myocyte development. FOXO: nuclear transcription factor; MEF2: myocyte enhancer factor-2.
in subcutaneous fat; yet they were higher in the pigs born
from mothers with late pregnancy recuperation suggesting
that leptin is programmed in utero.
By 2001, Thomas et al. [63] used the ewe adolescent
model to analyze the patter of secretion of leptin during
pregnancy. The ewes were subjected to a dietary regime from
moderate to high, or high to moderate food intake. Leptin
expression and protein were higher in those which were in
thehigheroverfedgroup,suggestingthattheproducedleptin
was a reﬂection of fat deposition in the mother due to over-
feeding. Moreover, there was a negative correlation between
maternal leptin levels and fetal and placental birth weight. In
the fetal sheep, leptin has been known to modulate energy-
expensive processes like angiogenesis and hematopoiesis. It
is expressed mostly in the brain and liver, but it can also
be found in fetal skeletal muscle, kidney, and perirenal
adipose depot. Mothers might have a negative correlation
with fetal weight; yet neonatal leptin levels do have a positive
correlation between birth weights in humans, and while
maternal nutrition modiﬁcation reduces serum leptin, it
does not aﬀect fetal concentrations [64]. These ﬁndings were
conﬁrmedbyM¨ uhlh¨ ausleretal.[65],whoanalyzedtheeﬀect
of nutrient intake on leptin levels in pregnant ewes during
the second half of pregnancy. They reported that increasing6 Journal of Obesity
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Figure 5: Nutrigenomics is a science that studies how food
components exert their inﬂuence on metabolism pathways and
manipulate genetic transcription, which can be used for disease
prevention.
maternal food intake elevated glucose but not leptin levels;
yet leptin was a good surrogate for fetal adiposity and
poses as a moderator of endogenous energy expenditure
in the fetus. Once more, in 2003 the same research team
published [66] thata moderate increase in maternal andfetal
supply modulates leptin and UCP1 expression, explained
by the progressive capacity of the unilocular adipose mass
to synthetize the proteins; these results propose that lipid
storage capacity is established during the prenatal period of
life.
Sheep models have been used to also evaluate the in
utero programming of glucose metabolism. Gardner et al.
[67] studied the eﬀects of early and late malnutrition in
sheep and evaluated its eﬀects on glucose metabolism at 1
year of age in the oﬀsprings of such animal subjects. The
study concluded that late gestation undernutrition (50% less
of requirements) inﬂuences glucose homeostasis, especially
when the maximal fetal growth is being achieved. Perhaps
one of the most interesting ﬁndings is that if the fetus
was under malnourishment since the beginning, there was
no signiﬁcant alteration in insulin sensitivity or in glucose
tolerance. Yet, those who starved during the second half of
the pregnancy had reduced GLUT4 expression, suggesting
that metabolic modiﬁcations are tissue-speciﬁc. The pre-
vious trial was conducted during late gestation showing
nonsubstantial ﬁndings on early pregnancy interventions,
but Ford et al. [68] published otherwise. This group reported
that malnourishment from early to midgestation in sheep is
related to increased body weight, fat deposition, and glucose
dysregulation compared to its counterparts in adolescence.
Anotherconclusionwasthebiphasiceﬀectofundernutrition
which associates with late gestation fetal and postnatal catch-
up growth, all consistent with the thrifty phenotype and
the accumulating data on fetal low-weightness in relation
to the onset of Diabetes Mellitus, associated with a rise in
Nutrient derived signals
Sensor dependent pathways
Sensitive genotype
Stress signature-disease
2nd hit:
Proinﬂammatory stress
1st hit:
Metabolic stress
Figure 6: The basic idea with nutrigenomics is to determine a
patient’spolymorphismsandformulateadietthatamelioratesthese
genetic factors to minimum, regulating and maintaining weight
loss.
the adipogenesis signaling cascade previous to the onset of
obesity [68].
The epigenetics involved in the “Small Baby” model
include methylation changes in fundamental genes which
control β-cell ontogeny and functional diﬀerentiation [39–
41, 69–72]. The Pancreatic and Duodenal Homeobox 1
(Pdx1) is a transcription factor which regulates the devel-
oping growth of the bud that will become the pancreas.
This factor shows progressive declining of transcription in
intrauterine growth retardation (IUGR), and it is associated
with epigenetic regulation via histone methylation. The GTP
cyclohydrolase 1 (Gch1) is part of the folate and biopterin
biosynthesis pathways and has been positively related to
endothelial dysfunction observed in diabetes. PDX1 is in
charge of modulating the expression of ﬁbroblast growth
factor receptor 1 (Fgfr1) which is involved in glucose home-
ostasis. In IUGR this gene is upregulated and it is related to
vesselmalfunctionandﬁbrosisofthepancreas.Finally,IUGR
is associated with lengthening of β-cell cycle, decreasing
the number of mitosis, contributing to insuﬃcient insulin
production in the postnatal life. Survival of the ﬁttest fetus
requires downregulation and shut-down of several stress
and energy sensors in liver and skeletal muscle, which is
advantageous during pregnancy, but has deleterious eﬀects
after birth, because nutrient sensing and insulin sensitivity
are compromised [73].Journal of Obesity 7
• Increases AMPK via ATP depletion
• Increases intracellular calcium
• Induces NOS
• Induces PKC
• Increases GLUT-4 translocation
• Increases glucose uptake
• Lowers hyperglycemia
• Enhances insulin sensitivity
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Figure 7: A few of the Metabolic beneﬁts obtained through exercise.
On a ﬁnal note, undernutrition in the fetus can alter
the food network “wiring” providing the tools for metabolic
disorders in the postnatal life. IUGR induces low levels
of leptin, which is involved in the nerve ﬁber projecting
towards the paraventricular nucleus from the POMC neuron
population, which are the anorectic ones [74, 75]. On the
contrary, maternal hypoxia and glucocorticoids exposure
of the fetus enhances Neuropeptide Y (NPY) expression
and secretion, having a role in fetal stress management
and setting up the hypothalamus network to orexigenic
signals [76, 77], especially since increased expression and
release on NPY is maintained postnatally [78]. In simpler
words, nutritional and hormonal factors may disturb the
proper development of the hypothalamus and its subsequent
function manifesting itself in eating habits-related disorders
[79, 80].
There is another theory which was developed to explain
the teratogenic ability of glucose—“The Fuel-induced terato-
genesis”. Freinkel et al. [81] proposed that fuel in the form
of hyperglycemia, is the very cause of diabetic embryopathy
and fetopathy associated with fuel excess. Various clinical
ﬁndings have proven this theory, especially in certain abo-
riginal population like the Pima Indians [82–85] and the
Paciﬁc Islanders [86–88] who have the highest prevalence
of Gestational Diabetes and macrosomia. Overnutrition is
knowntoenhancephysiologicalandepigeneticeﬀectsofglu-
cose, resulting in chronic hyperglycemia, hyperinsulinemia
and hyperleptinemia [89]. Fuel-induced cases are associated
with maternal obesity and/or diabetes rendering a speciﬁc
metabolic proﬁle: maternal hyperglycemia, hyperinsuline-
mia, and low-grade inﬂammation.
Since insulin cannot cross the placental barrier, glucose
is the main secretagogue in the fetal pancreas circa the
27th weeks of gestation. Skeletal muscle development is
crucial to adult life since it is responsible for the majority
of glucose and fatty oxidation rates. Macrosomic newborns
have visceromegaly and high amounts of adipose tissue,
but scarce development of the skeletal muscle, especially
type II ﬁbers which are responsible for the energy pro-
duction/aerobic capacities of the muscle. In a fuel-inducing
environment there is a mismatch between myogenesis and
adipogenesis, with chronic inﬂammation as the culprit
f o rt h i ss w i t c hi nd i ﬀerentiation [90–92] via inhibition of
AMPK, downregulation of WNT pathways, and epigenetic
modiﬁcations (see Figure 4).
2.2. Reversal of Fortune. Leptin has been considered the
pivotal molecule according to animal and human analysis;
yet its place was secured once it was proven that treatment
with it reversed the developmental programming that occurs
after maternal undernutrition during pregnancy [93]. Vick-
ers et al. used 2.5μg/g/day of leptin on rat pups born from
malnourished mothers, from day 3 to 13 of life, resulting
in normalization of caloric intake, voluntary motor activity,
body weight, glucose, insulin, and leptin levels, reversing
the prenatal programming [93], which seems to be gender-
speciﬁc and dependent of pre- and postnatal nutritional
status [94]. Alimentary intervention trials have also proven
to be eﬀective in reducing and/or preventing the adverse
outcomes of reprogramming, as it was shown by Wyrwoll et
al. [95] by using ω-3 fatty acids, and Zambrano et al. [96]b y
applying a dietary modiﬁcation strategy prior to pregnancy.
In summary, the intrauterine environment is the key
phase for acquiring the metabolic tools for surviving inside
the maternal womb; the dilemma is what happens when
the baby is born? Interestingly, these survival methods are
not without risk for the unborn fetus, since each of the
situations—IUGR and Macrosomia—carries a high risk
for stillbirth and immediate neonatal death [97–99]; every
change in the epigenetic make-up has a cost, and in the
pediatrics world, it is a high one. Growth restricted babies
are small for their gestational age, with small β-cell masses,
hypoleptinemia, and showing signs of “chronic hunger”,
while the Overfed fetuses are chubby, above the 90th weight
for their age, with elevated degree of fatness and decreased
muscle development. Both situations revolve around leptin
levels and AMPK intracellular signaling networks.
3. First Arrow:Nutrigenomics
“Nutrigenomics focuses on the eﬀect of nutri-
ents on the genome, proteome, and metabolome”
[100].8 Journal of Obesity
Dietandexercisearefundamentalpillarsinthetreatment
of overweight and obesity and related conditions such as
insulin resistance, cardiovascular disease, cancer, among
others. Several types of diets have been developed focusing
on determining a favorable macronutrient composition in
order to reach certain metabolic states that induce body
weight loss; see Figure 5 [101]. Initially, diet recommenda-
tions implied low-fat, moderate-protein, and relatively high
carbohydrate content diets, based on the fact that high-
fat diets induce less satiety [102] and that a diminishment
in diet fat consumption reduced signiﬁcantly the risk of
cardiovascular disease by lowering circulating lipids [103].
However, a paradoxical phenomenon was observed; subjects
on this diet began to gain weight, instead of losing it,
especially in Western countries.
Inresponsetothelackofeﬀectivenessofthesenutritional
recommendations, new dietary alternative schemes are been
developed. Dr. Atkins is one of the pioneers of the widely
popularized low-carbohydrate diets, with a low glycemic
index and high-ﬁber content [104]. These diets induce rapid
body weight loss, increased satiety [105], and an associated
reduction of cardiovascular disease and diabetes risk [106].
However, there are only a few long-term and adequately
randomized studies to recommend this type of diet [107,
108]. In the past decade, several studies have been carried
out to analyze the eﬀect of a high-protein content diet in
weightloss,demonstratingbodyweightreductionalongwith
a higher maintenance of this weight loss [109, 110]. Interest
in the development of these types of diets largely derives
from the theoretical eﬀect that diet composition can have on
energy consumption as well as on food consumption [111].
Studies on the physiological eﬀects of dietary composition
in human population turned out to be complicated because
of lack of compliance of the diet as well as accurate
reporting, which is why several animal models have been
developed in order to determine the eﬀects of diet on
metabolism and are the main source of information on this
topic.
Recognizing the central role of AMPK in controlling
energy balance, as a sensor of cellular energy quantum [112]
the following question is formulated: What are the eﬀects of
dietary components on the activity of AMPK?
3.1. Lipids and AMPK. Although the exact mechanism
linked to this phenomenon remains unknown, there is
substantial evidence that high-fat diet is a risk factor that
promotes obesity development, glucose homeostasis alter-
ations, and cardiovascular system disorders [113]. The main
metabolic manifestations of this diet are elevated free fatty
acids, decreased intracellular fatty acid oxidation, and lipid
accumulation on insulin-targeted organs [114]. A high-fat
diet is correlated with a decreased expression of mRNA for
the AMPK-α2 isoform as well as AMPK phosphorylation
with consequent decreased activity of this enzyme in skeletal
muscle, leading to decreased glucose uptake, meanwhile in
adiposetissueitpromotespreadipocytediﬀerentiation,lipol-
ysisandthesecretionofadipokines(TNFα),perpetuatingthe
process [115, 116].
AMPK has a crucial role in the hypothalamus’ food
intake control tower, constituting the signaling pathway of
several hormones—including leptin—to regulate satiety. A
high-fat diet induces hyperleptinemia which is associated
with both peripheral and central leptin-resistance [117].
Reduced hypothalamic levels of leptin activity may be due,
at least in part, to the constitutive alteration in the signaling
pathway of AMPK. In the paraventricular nucleus of mice
with diet-induced obesity, AMPK activity is constitutively
diminished, and in the arcuate and medial nucleus of the
hypothalamus leptin fails to suppress the activity of AMPK
[118]. It has also been shown that long-chain fatty acid
esters are able to inhibit AMPK kinase (AMPKK) and thus
downregulate the signaling cascade of this pathway [119].
Eicosapentanoic Acid (C20:5 ω3, EPA) and Docosahex-
anoic acid (C22;6 ω3, DHA) exert prophylactic eﬀects in
cardiovascular disease, protect against insulin resistance and
obesity in mice with high-fat diets, and improved insulin
response in humans. The administration of polyunsaturated
fatty acids has been shown to reduce the insulin resistance
causedbyhighlevelsofsaturatedfats[120,121].Ingestionof
diets rich in polyunsaturated fatty acids (PUFAs) has shown
to suppress hepatic lipogenesis, lower TAG-rich lipoproteins
synthesis in the liver, and increase fatty acid oxidation
and induction of genes that regulate fatty acid oxidation
(i.e., CPT1). A similar situation occurs in skeletal muscle
where PUFAs increase thermogenesis, fatty acid oxidation,
and glucose uptake. All these events are modulated by the
action of AMPK [122, 123]. The mechanism by which PUFA
may activate AMPK remains to be elucidated, but several
hypotheses have been proposed such as an increase in the
AMP/ATP ratio, decreased dephosphorylation of AMPK by
control over the activity of protein phosphatase 2A (PP2A),
or enhanced AMPK activity secondary to elevated plasma
levels of adiponectin, IL-6, leptin and others [124, 125].
Conjugated linoleic acid (CLA), a group of linoleic
acid isomer, has several physiological functions including
anticancer properties, decreased atherosclerotic process, and
modulation of the immune system [126, 127]. The CLA
decreases the expression of AMPK-α2 and satiety and
consequently decreases body weight [128].
Recent evidence suggests that short-chain fatty acids
produced by fermentation of carbohydrates in the intesti-
nal lumen could be absorbed and aﬀect hepatic glucose
metabolism [129]. The regulation of hepatic AMPK activity
could play a critical role in this process; yet there is
little data available on the eﬀect of short-chain fatty acids
on the activity of AMPK. In hepatocytes culture, acetate
activates AMPK activity probably by increasing the rate
AMP/ATP [130, 131]. Butyrate supplementation can prevent
the development of insulin resistance in mice by promoting
energy expenditure through the induction of mitochondrial
function [132].
3.2. Carbohydrates and AMPK. The deleterious eﬀect of a
high-carbohydrate diet on health is well known. Using the
current knowledge previously discussed here and the lack
of eﬀectiveness of low-fat diets, low-carbohydrate diets withJournal of Obesity 9
or without caloric restriction have been developed [133].
There is currently much interest in the potential role of
foodsglycemicindexinthemanagementofobesityandother
metabolic disorders. It has been shown that foods with low
glycemic index may be beneﬁcial in regulating body weight
in two ways: ﬁrst by promoting satiety and secondly by
increasing fatty acid oxidation, both explained by the action
of AMPK [134]. However, a number of mechanisms that
can be triggered by the glycemic index of foods consumed
in the diet may explain the variability in the results of
studiesofweightlossusingtheglycemicindex[135].Glucose
restriction provokes AMPK activation, resulting in the
inhibition of anabolic processes which consume ATP such
synthetic pathways for fatty acids, proteins, and cholesterol,
and activation of catabolic processes which generate ATP to
maintain cellular energy deposits like fatty acid and glucose
oxidation [135].
AMPK regulates myogenesis and diﬀerentiation of skele-
tal muscle and preadipocyte diﬀerentiation into mature
adipocytes, through SIRT1 (NAD-dependent deacetylase
sirtuin-1 [silent mating type informationregulation 2 homolog
1])[136].Thelossofdiﬀerentiationduetocellularstarvation
can be explained as a simple adaptation of a cell that is
incapable to sustain the energy demanding activities that
come with diﬀerentiation. Nevertheless, recent evidence
suggests that there is a pathway activated in low-calorie cel-
lular microambients, and it involves AMPK/Visfatina/SIRT1.
Visfatin is a new adipokine which exerts insulin-like actions
[137]. The pathway is characterized by AMPK-dependent—
SIRT-mediated induction of Visfatin, resulting in elevation
of the NAD+/NADH ratio, which induces genetic tran-
s c r i p t i o ns h u t d o w n[ 138, 139]. The beneﬁcial eﬀects of a
low-carbohydrate diet have been observed in short-term
trials, which warrant the need for long-term studies to
fully evaluate and fully recommend this type of nutritional
recommendation [140].
3.3. Proteins and AMPK. In the last 10 years, low-carbo-
hydrate diets with high protein intake have become really
popular. The evidence suggests that the main mechanism
for its success is that high protein ingestion promotes
weight loss by inducing thermogenesis and satiety [141].
Of course, it is not only the percentage of ingested protein
but also the quality and aminoacid proportion which
determines the loss-weight property [142, 143]. Proteins
exert their eﬀect in diﬀerent manners, from the intestinal
lumen with activation of chemoreceptors which respond
to aminoacid/peptide presence releasing cholecystokinine
(CCK), Glucagon-like peptide-1 (GLP-1), or peptide YY
to a higher central level, modulating neurotransmitter
release in middle cellular levelsregulating AMPK activity
[143, 144].
A high-protein diet is capable of controlling food intake
due to enhanced POMC expression and repression of NPY
in the hypothalamus, via activation of mTOR and low
phosphorylation rates of AMPK [145, 146]. Leucine aﬀects
AMPK pathway by inhibiting it, and in doing so, it
activates the mTOR signaling pathway. Intraventricular
injection of leucine in rats reduces food intake in a dose-
dependent manner, and this eﬀect is not observed with other
aminoacids. Although this is true, weight reduction and
food intake magnitude observe with the leucine treatment
was similar to that achieved by a high-protein diet, which
can explain why leucine is the most abundant aminoacid
in most of the protein-rich formulated diets [146]. The
exact mechanism for leucine AMPK-inhibiting activity is
unknown; yet it probably relates to allosteric activation of
the Glutamate Dehydrogenase (GDH) resulting in elevated
substrate ﬂux towards Krebs cycle (via glutamate conversion
to α-ketoglutarate), lowering AMP/ATP ratio, and reducing
AMPK phosphorylation [147].
Alternative medicine has been a huge source of nat-
ural products now used in obesity and insulin resistance
treatment, but the vast majority of the cases lack scien-
tiﬁc evidence which can vouch for its eﬃciency and the
mechanism of action is usually unknown. The bitter melon,
Momordicacharantia (Cucurbitaceae), is an Asian cultivated
plant that is used as a herbal medicine and has gained
fame for its hypoglycemic eﬀects in animal models and
humans [148]. Triterpenoids are the main constituent of
the fruit but the active principle has not been found yet.
In a recent study by Tan et al. [149], they reported that
curbitanetriterpenoids (Mormodicoside S,a n dkaravilosede
XI) are capable of stimulating AMPK activity, favoring
GLUT4 translocation, weight loss, and metabolic control.
The Phytoalexin resveratrol (trans-revestrol) is naturally
produced by bacteria or some fungi species. This polyphenol
is capable of enhancing AMPK, SIRT1, and Peroxisome pro-
liferator activated-receptor gamma coactivator 1-α (PGC1-
α), reducing Insulin-like growth factor 1 levels enhancing
insulin sensitivity [150, 151]. Berberine is an alkaloid found
in a plant cultivated in Asia, used mainly in Korea and China
for several diseases including diabetes treatment in humans
[152]. Berberine acutely stimulates AMPK in myocytes and
adipocytes, inducing GLUT4 translocation and lowering fat
storage in adipose tissue. This substance also decreases the
diﬀerentiation rate of preadipocytesby of PPARγ by p38MAPK
phosphorylation, whose activity seems to be enhanced by
berverine [153, 154].
There is no doubt that nutrition is fundamental to
obesity development and other major chronic diseases
like CVD and T2DM, and this is especially true in the
pediatric population where scientists have seen a rise in
caloric ingestion based on saturated fat and cholesterol with
associated low energy expenditure. Several diet regimes have
been devised; yet there are not enough trials to validate them
[155, 156]. It is extremely necessary to design and undertake
randomized trials to evaluate the nutrigenomic properties
of food and apply them to individualized diets [157]; see
Figure 6.
4. Second Arrow: Metformin
Even though there is growing evidence published every day
concerning childhood obesity, the use of pharmacological
treatment in them is still in controversy. The complexity10 Journal of Obesity
of this disease has delayed data gathering, most of which
is extrapolated—not without diﬃculty—from large general
population trials. It is noteworthy to add that there is no
magical drug for weight loss, and most of the guidelines
recommend pharmacological treatment after lifestyle mod-
iﬁcation and diet regime have failed to meet the primary
goals, and that implementation of drug therapy has to be
accompanied by diet and exercise [158, 159].
There are only 2 drugs FDA (Food and Drugs Admin-
istration) approved for obesity treatment in the pediatric
population: Orlistat and Sibutramine [160]. Orlistat is a
gastric and pancreatic lipase inhibitor, which lowers fat
absorption favoring weight loss. Small pilot studies were
undertaken in children and adolescents, measuring it is
safety and tolerability. This drug was approved by the FDA
in 2003 as treatment for obesity in children beyond 12
y e a r so fa g e s[ 161, 162]. On the other hand, Sibutramine
is a serotonin-norepinephrine-dopamine reuptake inhibitor,
which induces weight loss via appetite suppression, which is
FDA approved for adolescents above 16 years old [163, 164].
Metformin is a molecule widely used in the treatment of
T2DM in children above 10 years old. The drug’s mechanism
of action is still partially understood; yet in 2001 there was
a major breakthrough when Zhou et al. [165] observed that
AMPK plays a fundamental role in this puzzle. Since neither
Orlistat nor Sibutramine modulates AMPK, we will analyze
the weight reduction eﬀect of metformin applied to obese
children and adolescents.
As was mentioned previously, metformin is used in
T2DMduetoitsinsulinsensitizingeﬀects,whichareeﬃcient
in the treatment of Polycystic Ovary Syndrome, T2DM,
and Hepatic Steatosis. These applications have revealed that
patients obtain and maintain weight reduction, making the
science community take a closer look at metformin and
its inﬂuence in appetite control [166, 167]. Freemark and
Bursey [168] was one of the ﬁrst researchers to acknowledge
metformin’s eﬃciency on weight loss in a double-blind
case-controlled trial with 29 adolescents who had fasting
hyperinsulinemia and T2DM family history, using 500mgs
twice a day versus placebo tablets for a period of 6
months. The study reported a 0,12 decrease SD in BMI,
while there was an increase Standard Deviation (SD) of
0,23 in the placebo group. Similar ﬁndings were published
by Srinivasan et al. [169] who conducted a randomized
controlled trial comparing metformin (1gram twice a day)
versus placebo in 28 obese patients between 9–18 years old.
The metformin group had the highest reduction in BMI
(−1.26Kg/m2), in weight (−4.35kg), waist circumference
(−2.8cms), and in fasting insulin levels (−2.2mU/L). In
2008, Burgert et al. [170] published their results on the
cardiometabolic beneﬁts of metformin in 28 morbidly obese
adolescents patients, who were randomized and divided into
2 groups, one receiving metformin 1,500mgs daily (n =
15), and the placebo group for 4 months. The placebo
group had elevation of BMI (1.1kg/m2); meanwhile, the
treatment group had reduction in this criteria (−0.9kg/m2).
Comparedwithplacebo,themetformingrouphadenhanced
insulin sensitivity, subcutaneous (but not visceral) fat
reduction—data which dissents from the one reported by
Srinivasan—and obtained cardiovascular function improve-
ment.
Love-Osborne et al. [171] investigated the eﬀects of
metformin in a lifestyle modiﬁcation program in insulin
resistant adolescents. This was a randomized, controlled
double-blind trial with 85 obese adolescents with insulin
resistance who were divided into 2 groups, placebo and
treatment group who received 850mgs twice a day. The
patients who ﬁnished the study and who maintained the
treatment had the highest BMI reduction, with an estimated
BMI reduction of 5% or more. Casteels et al. [172] studied
42 obese teenagers with motor deﬁcit who had low physical
ﬁtness and elevated body fat. This study was conducted to
analyze metformin’s weight control properties compared to
placebo. Six months of therapy oﬀered weight and BMI
reduction, due to lower visceral fat. Finally, earlier this
year The Glaser Pediatric Research Network Obesity Study
Group [173] did a 48-week Metformin Extended Release
(1gram twice a day) trial in 77 obese adolescents(13–
18 years old), concluding that the drug caused signiﬁcant
BMI reduction, and this eﬀect lasted after 12–24 weeks of
treatment cessation.
Even though the studies are promising, they have the
disadvantage of being conducted with small patient samples
for short periods of time. In this matter, the REACH-
Activity and Metformin Intervention in Obese Adolescents
study is underway [174], applying a 2-year protocol with
metformin (1,500 grams daily) and with physical activity.
The recruitment is focused on obese patients between 10–
16 years old alongside their parents, which will be randomly
controlled and assigned drug or placebo. The preliminary
results are expected in the end of 2010 with the complete
results of this intervention to be published in 2012.
5. Third Arrow: PhysicalActivity/Exercise
Perhaps the grayest area in childhood obesity is how much is
enough physical activity in the child and adolescent because
several factors are at play here: age, gender, geography
and seasoning, race, psychological factors, ecological factors,
sociocultural determinants, and school activities, among
others [175]. Physical activity in the pediatrics population
is not only beneﬁcial to cardiometabolic health, but it also
serves as a psychological tool to improve behavioral well-
beingandlowertheincidenceofdrugs,smoking,earlysexual
activity, and other problematic habits, shaping the lifestyle
pattern the child will have as a grown adult. Overweight
children and adolescents are prone to acquire risk factors
associated with CVD, are likely to become obese adults,
predisposed to inappropriate dieting practices like anorexia
or bulimia, physical inactivity, alcohol, and tobacco use, have
obesity-related health issues like asthma, sleep apnea, T2DM
and nonalcoholic hepatic steatosis, and ﬁnally, are at high
risk for long-term chronic disease, like stroke, cancer, and
gall bladder disease [176].
Physical activity can be deﬁned as any movement
produced by the skeletal muscles which ends in energy
consumption and can be measured in kilocalories [177].Journal of Obesity 11
Another deﬁnition is any daily activity of at least 30 minutes
(occupational, leisure, home-related), which can be vigorous
or moderate, planned or unplanned, and is inserted in the
daily lifestyle of the subject [178]. Exercise is immerged in
the concept of physical activity, and the diﬀerence between
them relies in the very fact that exercise has a physical ﬁtness
purpose [177, 178] .H o wm u c ho rw h a tt y p eo fe x e r c i s ec a n
be recommended for the patients is still in controversy, since
it depends on comorbidities, age, psychological status, and
aerobic capacity [179].
5.1.GrowingUp. Oneofthemainissuesaboutpediatricobe-
sity is the age of appearance and growth sprouts throughout
adolescence until adulthood. We have already discussed the
intrauterinemilieusinprevioussections,and3outcomescan
be concluded: the growth restricted, a normal weight, and
the macrosomic newborns. The small baby and the big baby
are at high risk for early infant growth which is associated
with subsequent obesity in adulthood [180]. In babies fed
with milk-formulas, rapid weight gain during the ﬁrst weeks
of life is determinant for obesity several decades later [181];
meanwhile breast-fed babies are inversely correlated with
adult obesity regardless of the mother’s weight or glucose
tolerance, highlighting the protective eﬀect of breast milk
[182]. BMI increases steadily and rapidly as the baby grows
into a toddler and towards infancy reaching a minimum
plateau at around 5–6 years of age, which is denominated
BMI rebound (or adiposity rebound (AR)). Several studies
have linked early rebound to increase risk of obesity in later
life [183–186], especially in children who were tall at 3 years
of age [187]. The third critical period phase is adolescence,
which is elementary to determine the probability of adult
obesity. During this phase, gender takes its toll in risk
assessment, and girls are in a bit more danger than the boys
to become obese, since sexual maturation comes with fat
increase. Around 80% overweight adolescents will become
obese adults, and in light of this data, intervention measures
must be installed.
Adiposity rebound has gathered a fair amount of atten-
tion since the mid 80s when the ﬁrst associations were made
with obesity [188]. The phenotype of early rebounders is
characterized by diﬀerent velocities for height and weight
gaining, varying in each child, with basic features as
advanced bone age [189], early menarche [190], and later
obesity[191].Whitakeretal.[192]conductedaretrospective
cohort study with 390 patients and their parents, reporting
that the mean age for AR was 5,5 years, and by adulthood,
15% of the subjects were obese—with higher rates in those
who were earlier and heavier rebounders and those who
had heavier parents. The following year, Eriksson et al.
[193] published that the highest death rates occurred in
boys who were SGA at birth but had an early catch-up
phase with normal or above average rates when compared
to normal counterparts. Later, Velasquez-Mieyer et al. [194]
undertook a cohort study analyzing 25 risk factors for AR,
determining that 8 were the most prevalent among 909
subjects from Great Britain: parental obesity, very early
AR (by 43 months), more than 8 hours spent watching
television per week at the age of 3, presence of catch-up
growth, weight gain during the ﬁrst year, birth weight, short
sleep duration at age 3, and standard deviation score at
age 8 and 18 months. These features are in agreement with
factors used to identify high-risk youngsters, as published
by Velasquez-Mieyer et al. [194]: placental insuﬃciency,
gestationaldiabetes,maternaloverweight/obesityandweight
gain during pregnancy, SGA, LGA, infant overnutrition,
bottle feeding, drug induced weight gain, early AR, and
overweightness during adolescence.
Yet, the question rises, during which phase must inter-
vention be applied? Several studies have proven that BMI
rebound is in fact the most critical and determinant
phase of the 3, and measures should be taken to improve
adiposity in this children [187, 189, 192, 195–197], since
early intervention is the best option to void adolescence
obesity, and later adult obesity. According to the Physical
A c t i v i t ya n dH e a l t hC D Cr e p o r t[ 198]a l lp e o p l ea b o v e2
years of age should do at least 3 minutes of endurance-
type of physical activity, at least of moderate intensity,
preferably every day of the week. The problem in this
statement is that children below 6 years old might not
comprehend the object of physical activity; so planned
sequential exercise should be substituted with programmed
school activities which guarantee moderate activity for over
30 minutes. Young children are not physically adept to be
subjected to adolescent or adult physical activity regimes;
therefore the guidelines must be developed in accordance
with this fact. The Framingham Children’ Study [199–201]
revealed several aspects that need to be addressed during
this period: parental involvement in the physical activities
and nutritional intervention, elevated TV viewing time, and
nutrient tracking.
5.2.TheBeneﬁtsofAMPK. Exercisehasseveraladvantageous
properties which makes it appropriate to include it in the
day-to-day life of a high-risk child/adolescent. The primary
eﬀects of exercise include enhanced GLUT4 translocation via
insulin-independent pathways which include Nitric Oxide
synthesis and AMPK activation (see Figure 7). AMPK is
activated via phosphorylation of Thr172 by AMPK kinase or
Calmodulin dependent kinase (CaMKK). Once this enzyme
is activated, it phosphorylates atypical Protein Kinase C
(PKC) which stimulates phosphatase that will act upon
IRS1, leaving the insulin pathway unopposed to induce
Akt and glucose transporter translocation. Moreover, AMPK
induces the expression of GLUT4 gene through MEFA2A
and MEFA2D (factor 2a myocyte enhancer). During AMPK
activation, it will inhibit AcetilCo∼ACarboxilase 2 (ACC2),
lowering Malonyl∼CoA concentrations, spiking β-oxidation
of fatty acids [202].
It has also been suggested that exercise exerts anti-
inﬂammatory eﬀects which are eﬀective in aiding the low-
grade inﬂammation that characterizes adult obesity [203],
and it is not diﬀerent in childhood/adolescent obesity [204,
205]. Weiss et al. [206] published that adiponectin inversely
correlates with C-Reactive Protein (CRP) levels, while the
latter and IL-6 were in direct relation to BMI. In children12 Journal of Obesity
between 8–16 year olds, being overweight is associated with
elevated white blood count and CRP suggesting low-grade
inﬂammation in these children [164]. Hypoadiponectinemia
has been independently associated with metabolic syndrome
in teenagers, which has upgraded adiponectin to a high
CVD risk [207, 208], alongside with IL-6, and IL-18 [209–
211]. When skeletal muscles exercise, they release a 100-
fold of IL-6, with a concomitant release of IL-10 and IL-1
receptor antagonist [212, 213], serving as powerful immune
modulators that interfere with the metainﬂammation that
characterizes obesity.
6. Conclusions andRecommendations
Obesity in the pediatrics population has been a major public
concern since the late 1970s [214]. Several steps have been
taken to undermine the situation, but somehow it has gotten
out of hand [215]. The Healthy People Program has a
primary goal 5% or less prevalence of obesity in children
and adolescents, increases school nutrition education, and
increases the number (>7 5 % )o fp r i m a r yc a r ep r o v i d e r s
who are able to handle overweight reduction services
[216]. Behavioral and motivational interventions have to
go together with any of the primary tools: diet, exercise,
and/or drug. The sticking to the program depends highly
on this aspect, since children and adolescents are susceptible
of depression, anxiety, impaired family functioning, poor
psychological adaptation, and eating disorders behavior
[216–218].
Understanding the etiology of a disease is the best way
to conquer it: attacking key points in the natural history
will help eliminate the progression of the disease. In this
light it has been proposed that BMI rebound is the key
aspect in high-risk children; nevertheless, the other two
stages (prenatal and adolescent) are still important; yet
the prenatal state depends on the mother’s condition and
comorbidities, while the adolescence phase is modulated
by sexual hormones which will inevitably take its toll.
So, success at halting obesity will be achieved with early
interventions during infancy. School-associated programs
for physical activity seem to be gaining popularity because
they have been shown to reduce weight gain, visceral adipose
tissue, and reduces remission of obesity [219–221]. Mallare
et al. [222] recommended physical activity of 30–60-minute
duration a day and lowering sedentary activities to less than
2h o u r sad a y .
In the era of the “omics”, each treatment has to be
individualized as much as possible, since each patient is
a new case. A full history chart and complete blood and
anthropometrical work-up will help to assess the main fac-
tors involved in the progression of the disease. Nevertheless,
AMPK seems to be involved in virtually every aspect of
the disease, serving a pivotal role. There is little doubt that
common obesity is a multifactorial disease, and targeting
the major intracellular components will beneﬁt weight loss
management and continuum of the program. More studies
are needed to fully approve the use of Metformin as a
weight-loss drug, like Orlistat and Sibutramine; yet its
pharmacological properties make it the drug of choice in
obesity treatment. A nutriogenomically guided diet will
aid in the reorganization of the cellular energy status, and
exercise will enhance glucose uptake and lipid oxidation,
improving the metabolic proﬁle of these youngsters.
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